Cargando…

Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?

Background: This study aims to analyse whether in acute heart failure (AHF) with iron deficiency (ID), the administration of ferric carboxymaltose (FCM) produces a greater benefit in renal dysfunction. Methods: A total of 812 consecutive patients admitted for AHF and ID were studied. Untreated (n:27...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Vilella, Raquel, Guerrero Cervera, Borja, Donoso Trenado, Víctor, Sánchez-Lázaro, Ignacio, Martínez Dolz, Luis, Almenar Bonet, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144873/
https://www.ncbi.nlm.nih.gov/pubmed/37109444
http://dx.doi.org/10.3390/life13040915
_version_ 1785034198350823424
author López-Vilella, Raquel
Guerrero Cervera, Borja
Donoso Trenado, Víctor
Sánchez-Lázaro, Ignacio
Martínez Dolz, Luis
Almenar Bonet, Luis
author_facet López-Vilella, Raquel
Guerrero Cervera, Borja
Donoso Trenado, Víctor
Sánchez-Lázaro, Ignacio
Martínez Dolz, Luis
Almenar Bonet, Luis
author_sort López-Vilella, Raquel
collection PubMed
description Background: This study aims to analyse whether in acute heart failure (AHF) with iron deficiency (ID), the administration of ferric carboxymaltose (FCM) produces a greater benefit in renal dysfunction. Methods: A total of 812 consecutive patients admitted for AHF and ID were studied. Untreated (n:272) and treated (n:540) patients were compared. The six-month prevalence of a combined event (readmission for HF, all-cause death, and emergency department visit for decompensation) was analysed. Three grades of renal dysfunction (KDIGO) were compared, Group 1 (grades 1 and 2), Group 2 (grades 3a and 3b), and Group 3 (grades 4 and 5). Results: There were differences in sex distribution (untreated group: males 39.7% vs. treated group: males 51.9%; p < 0.001). Sex-adjusted combined event analysis showed a greater benefit in Group 1 (OR: 0.31, 95% CI:0.19–0.5; p < 0.001) and Group 2 (OR: 0.23, 95% CI:0.14–0.38; p < 0.001), but not in Group 3 (OR: 0.51, 95% CI:0.17–0.55; p: 0.237). Conclusions: The administration of FCM in patients with AHF and ID reduces the combined event analysed. The benefit is greater when renal dysfunction is present, except in very advanced degrees where no significant benefit is obtained.
format Online
Article
Text
id pubmed-10144873
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101448732023-04-29 Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction? López-Vilella, Raquel Guerrero Cervera, Borja Donoso Trenado, Víctor Sánchez-Lázaro, Ignacio Martínez Dolz, Luis Almenar Bonet, Luis Life (Basel) Article Background: This study aims to analyse whether in acute heart failure (AHF) with iron deficiency (ID), the administration of ferric carboxymaltose (FCM) produces a greater benefit in renal dysfunction. Methods: A total of 812 consecutive patients admitted for AHF and ID were studied. Untreated (n:272) and treated (n:540) patients were compared. The six-month prevalence of a combined event (readmission for HF, all-cause death, and emergency department visit for decompensation) was analysed. Three grades of renal dysfunction (KDIGO) were compared, Group 1 (grades 1 and 2), Group 2 (grades 3a and 3b), and Group 3 (grades 4 and 5). Results: There were differences in sex distribution (untreated group: males 39.7% vs. treated group: males 51.9%; p < 0.001). Sex-adjusted combined event analysis showed a greater benefit in Group 1 (OR: 0.31, 95% CI:0.19–0.5; p < 0.001) and Group 2 (OR: 0.23, 95% CI:0.14–0.38; p < 0.001), but not in Group 3 (OR: 0.51, 95% CI:0.17–0.55; p: 0.237). Conclusions: The administration of FCM in patients with AHF and ID reduces the combined event analysed. The benefit is greater when renal dysfunction is present, except in very advanced degrees where no significant benefit is obtained. MDPI 2023-03-31 /pmc/articles/PMC10144873/ /pubmed/37109444 http://dx.doi.org/10.3390/life13040915 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
López-Vilella, Raquel
Guerrero Cervera, Borja
Donoso Trenado, Víctor
Sánchez-Lázaro, Ignacio
Martínez Dolz, Luis
Almenar Bonet, Luis
Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
title Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
title_full Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
title_fullStr Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
title_full_unstemmed Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
title_short Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
title_sort is the benefit of treating iron deficiency greater in acute heart failure with renal dysfunction?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144873/
https://www.ncbi.nlm.nih.gov/pubmed/37109444
http://dx.doi.org/10.3390/life13040915
work_keys_str_mv AT lopezvilellaraquel isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction
AT guerrerocerveraborja isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction
AT donosotrenadovictor isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction
AT sanchezlazaroignacio isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction
AT martinezdolzluis isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction
AT almenarbonetluis isthebenefitoftreatingirondeficiencygreaterinacuteheartfailurewithrenaldysfunction